Feline Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Vaccine

MODIFIED LIVE VIRUS
MODIFIED LIVE CHLAMYDIA

To Reconstitute: Rehydrate the vaccine with the sterile diluent for vaccination.

FELINE RCP+Ch Injectable

25 Vials (1 dose)
STERILE DILUENT
25 Vials (1 mL)

FELINE RCP+Ch Injectable

25 Vials (1 dose)
STERILE DILUENT
25 Vials (1 mL)

This product has been shown to be effective for the vaccination of healthy cats 12 weeks of age or older against feline herpesvirus-1 (FHV), feline calicivirus (FCV), feline parvovirus (FPV), and Chlamydia psittaci. Duration of immunity has not been established. For more information regarding efficacy and safety data, go to products.vetinfo.usda.gov.

In cats vaccinated and transferred as kittens, and then vaccinated again approximately 1 year later, revaccination has been demonstrated to result in serum antibody titers that persist for 12–30 months against FPV hemagglutination inhibition (HI) titer ≥ 1:40, FCV plaque neutralization (PN) titer ≥ 1:32, and FHV (SN) titer ≥ 1:16.

Directions: Administer 1 dose intramuscularly or subcutaneously. Healthy cats 12 weeks of age or older should receive 2 doses administered 3–4 weeks apart. Vaccinate healthy cats, except that if the animal is less than 16 weeks of age, the first dose should be given no earlier than 16 weeks of age. Historically, annual revaccination with this product was recommended. The need for annual booster vaccinations has not been established; consultation with a veterinarian or the manufacturer is recommended.

Precautions: Store at 2°–8°C. Do not freeze. Sterilized syringes and needles should be used to administer the vaccine. Do not sterilize with chemicals because traces of disinfectant may inactivate the vaccine. Inactive unused contents before disposal. Contains gentamicin as a preservative. This product is not tested in pregnant animals. The use of this product has been associated with fever, anorexia, and lethargy in 1% of vaccinated cats, often occurring in clusters in association with multiple concurrent vaccinations. The onset is typically delayed 1–21 days after vaccination. Symptoms may persist for 3–30 days with an average of 12 days after onset. Veterinary intervention may be required. When treatment is necessary, supportive care, steroids, and antibiotics have been utilized. As with many vaccines, anaphylaxis may occur after use. Initial atopy of epinephrine is recommended and should be followed with appropriate supportive therapy. Do not mix with other products, except as specified on the label. In case of human exposure, contact a physician. Technical inquiries should be directed to Zoetis Inc. Veterinary Services, (888) 963-8471.

This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.

4X033018